Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to ...
GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback